Switch theme
Sign up to access all valuation multiples
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
2000
24.4K+
LTM Revenue $4.5B
LTM EBITDA $1.0B
$9.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sino Biopharmaceutical has a last 12-month revenue (LTM) of $4.5B and a last 12-month EBITDA of $1.0B.
In the most recent fiscal year, Sino Biopharmaceutical achieved revenue of $3.7B and an EBITDA of $880M.
Sino Biopharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sino Biopharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.5B | XXX | $3.7B | XXX | XXX | XXX |
| Gross Profit | $3.7B | XXX | $3.0B | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $1.0B | XXX | $880M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $882M | XXX | $820M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $510M | XXX | $447M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sino Biopharmaceutical's stock price is HKD 4 (or $1).
Sino Biopharmaceutical has current market cap of HKD 79.6B (or $10.2B), and EV of HKD 74.1B (or $9.5B).
See Sino Biopharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.5B | $10.2B | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sino Biopharmaceutical has market cap of $10.2B and EV of $9.5B.
Sino Biopharmaceutical's trades at 2.6x EV/Revenue multiple, and 10.7x EV/EBITDA.
Equity research analysts estimate Sino Biopharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sino Biopharmaceutical has a P/E ratio of 21.7x.
See valuation multiples for Sino Biopharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.2B | XXX | $10.2B | XXX | XXX | XXX |
| EV (current) | $9.5B | XXX | $9.5B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBIT | 11.7x | XXX | 11.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.7x | XXX | 22.8x | XXX | XXX | XXX |
| EV/FCF | 14.3x | XXX | 14.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSino Biopharmaceutical's last 12 month revenue growth is 12%
Sino Biopharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Sino Biopharmaceutical's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sino Biopharmaceutical's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sino Biopharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sino Biopharmaceutical acquired XXX companies to date.
Last acquisition by Sino Biopharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Sino Biopharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sino Biopharmaceutical founded? | Sino Biopharmaceutical was founded in 2000. |
| Where is Sino Biopharmaceutical headquartered? | Sino Biopharmaceutical is headquartered in Hong Kong. |
| How many employees does Sino Biopharmaceutical have? | As of today, Sino Biopharmaceutical has 24.4K+ employees. |
| Who is the CEO of Sino Biopharmaceutical? | Sino Biopharmaceutical's CEO is Mr. Eric S Y Tse. |
| Is Sino Biopharmaceutical publicy listed? | Yes, Sino Biopharmaceutical is a public company listed on HKG. |
| What is the stock symbol of Sino Biopharmaceutical? | Sino Biopharmaceutical trades under 01177 ticker. |
| When did Sino Biopharmaceutical go public? | Sino Biopharmaceutical went public in 2003. |
| Who are competitors of Sino Biopharmaceutical? | Similar companies to Sino Biopharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sino Biopharmaceutical? | Sino Biopharmaceutical's current market cap is $10.2B |
| What is the current revenue of Sino Biopharmaceutical? | Sino Biopharmaceutical's last 12 months revenue is $4.5B. |
| What is the current revenue growth of Sino Biopharmaceutical? | Sino Biopharmaceutical revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Sino Biopharmaceutical? | Current revenue multiple of Sino Biopharmaceutical is 2.3x. |
| Is Sino Biopharmaceutical profitable? | Yes, Sino Biopharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sino Biopharmaceutical? | Sino Biopharmaceutical's last 12 months EBITDA is $1.0B. |
| What is Sino Biopharmaceutical's EBITDA margin? | Sino Biopharmaceutical's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Sino Biopharmaceutical? | Current EBITDA multiple of Sino Biopharmaceutical is 9.9x. |
| What is the current FCF of Sino Biopharmaceutical? | Sino Biopharmaceutical's last 12 months FCF is $718M. |
| What is Sino Biopharmaceutical's FCF margin? | Sino Biopharmaceutical's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Sino Biopharmaceutical? | Current FCF multiple of Sino Biopharmaceutical is 14.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
